Melatonin may improve sleep, quality of life in patients with breast cancer
the ONA take:
Melatonin may be a potential therapeutic agent for improve sleep and quality of life in patients with metastatic breast cancer, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
Because fatigue and sleep problems are common among patients with cancer, researchers at the Sunnybrook Odette Cancer Centre in Toronto, Ontario, sought to investigate the effectiveness of melatonin at improving sleep.
For the phase 2 study, researchers enrolled 32 patients with metastatic breast cancer who were receiving hormonal or trastuzumab therapy. All participants took melatonin 5 mg at bedtime for 2 months.
Results showed that bedtime melatonin was associated with a significant improvement in subjective sleep, fatigue severity, sleep fragmentation and quantity, and quality of life.
The findings suggest that further research assessing the efficacy of melatonin for improving sleep and quality of life in patients with cancer is warranted.
Melatonin may be a potential therapeutic agent for improve sleep and quality of life in patients with metastatic breast cancer.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|